SBIO
ALPS Medical Breakthroughs ETF
Price Chart
Latest Quote
$63.44
-2.09 (-3.19%)
Current Price
| Previous Close | $65.53 |
| Open | $65.55 |
| Day High | $65.22 |
| Day Low | $63.01 |
| Volume | 70,602 |
Fund Information
| Net Assets | $190.42M |
| Expense Ratio | 0.50% |
| Category | Health |
| Fund Family | ALPS |
| Net Asset Value | $65.12 |
| Premium/Discount | -2.58% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $63.89 |
| SMA50 | $57.46 |
| SMA200 | $51.45 |
| RSI | 56.04 |
| ATR | 1.9958 |
| Rel Volume | 0.67 |
Performance History
| Week | -3.01% |
| Month | +22.42% |
| Quarter | +15.66% |
| 6 Months | +24.24% |
| YTD | +29.98% |
| Year | +97.22% |
| 3 Years | +113.50% |
| 5 Years | +37.80% |
| 10 Years | +196.96% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $65.20 | 39,800 |
| 2026-07-16 | $63.44 | 71,900 |
| 2026-07-15 | $65.53 | 31,600 |
| 2026-07-14 | $65.29 | 46,600 |
| 2026-07-13 | $65.33 | 76,000 |
| 2026-07-10 | $67.22 | 61,800 |
| 2026-07-09 | $68.94 | 59,700 |
| 2026-07-08 | $68.31 | 120,200 |
| 2026-07-07 | $67.84 | 77,400 |
| 2026-07-06 | $64.84 | 78,600 |
| 2026-07-02 | $64.90 | 49,900 |
| 2026-07-01 | $63.35 | 84,600 |
| 2026-06-30 | $64.65 | 70,300 |
| 2026-06-29 | $64.59 | 46,800 |
| 2026-06-26 | $63.25 | 43,200 |
| 2026-06-25 | $61.37 | 46,500 |
| 2026-06-24 | $60.84 | 79,100 |
| 2026-06-23 | $59.14 | 40,700 |
| 2026-06-22 | $58.66 | 44,600 |
| 2026-06-18 | $55.11 | 15,100 |
About ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
đ° Latest News
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Zacks âĸ 2026-07-09T10:20:01Z
A Few Reasons Why Small-Cap ETFs Are Good Bets Now
Zacks âĸ 2026-04-09T12:00:00Z
ETF Winners & Losers of Q1 2026
Zacks âĸ 2026-04-02T15:00:00Z
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
Zacks âĸ 2026-01-06T16:00:00ZBiotech ETFs Hovering Around a 52-Week: Here's Why
Zacks âĸ 2025-10-30T13:00:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.